Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Avecho Biotechnology Ltd
AVEAvecho Biotechnology Limited, a biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. The company operates through Production and Human Health segments. It also produces and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. In addition, the company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. Further, it develops feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney for treatment of osteoarthritis. The company was incorporated in 1992 and is based in Clayton, Australia. Address: 2A Westall Road, Clayton, VIC, Australia, 3168
Analytics
Zielpreis von Wall Street
2.6 AUDKGV
–Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen AVE
Dividenden-Analyse AVE
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
1 JahrAusschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende AVE
Bewertung der Aktie AVE
Finanzen AVE
Ergebnisse | 2019 | Dynamik |